



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110997 A1

(51) International Patent Classification⁷: **C07D 207/26**,
403/10, 417/12, 417/14, A61K 31/402, 31/4025, A61P
7/02

(21) International Application Number:
PCT/EP2004/006604

(22) International Filing Date: 17 June 2004 (17.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0314369.0 19 June 2003 (19.06.2003) GB
0405774.1 15 March 2004 (15.03.2004) GB

(71) Applicant (for all designated States except US): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BORTHWICK,
Alan, David** [GB/GB]; GlaxoSmithKline, Gunnels Wood


Road, Stevenage Hertfordshire SG1 2NY (GB). **HAR-
LING, John, David** [GB/GB]; GlaxoSmithKline, Gunnels
Wood Road, Stevenage Hertfordshire SG1 2NY (GB).
IRVING, Wendy, Rebecca [GB/GB]; GlaxoSmithK-
line, Gunnels Wood Road, Stevenage Hertfordshire
SG1 2NY (GB). **KLEANTHOS, Savvas** [GB/GB];
GlaxoSmithKline, Gunnels Wood Road, Stevenage Hert-
fordshire SG1 2NY (GB). **WATSON, Nigel, Stephen**
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Steve-
nage Hertfordshire SG1 2NY (GB). **YOUNG, Robert,
John** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB).

(74) Agent: **BAKER, Suzanne, Jane**; GlaxoSmithKline, Cor-
porate Intellectual Property (CN925.1), 980 Great West
Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA



(57) Abstract: The invention relates to compounds of formula (I): wherein: R¹ represents a group selected from: formula (II), each ring of which optionally contains a further heteroatom N, Z represents an optional substituent halogen, alk represents alkylene or alkenylene, T represents S, O or NH; R² represents hydrogen, -C₁₋₆alkyl, -C₁₋₃alkyl-CONR^aR^b, -C₁₋₃alkylCO₂C₁₋₄alkyl, -CO₂C₁₋₄alkyl or -C₁₋₃alkylCO₂H; R^a and R^b independently represent hydrogen, -C₁₋₆alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by C₁₋₄alkyl, and optionally the S heteroatom is substituted by O, i.e. represents S(O)_n; n represents 0-2; X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C₁₋₄alkyl, -C₂₋₄alkenyl, -CN, -CF₃, -NR^aR^b, -C₀₋₄alkylOR^c, -C(O)R^f and -C(O)NR^aR^b; R^c represents hydrogen or -C₁₋₆alkyl; R^f represents -C₁₋₆alkyl; Y represents hydrogen or C₁₋₄alkyl optionally substituted by halogen (e.g. CF₃, -CH₂CF₃); R^e and R^d independently represent hydrogen, -C₁₋₆alkyl, -C₁₋₄alkylOH, or together with the N atom to which they are bonded form a 4-, 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by C₁₋₄alkyl; and/or pharmaceutically acceptable derivative thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.



KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.